Suvorexant patent expiry?

When does the suvorexant patent (and exclusivity) expire?

Suvorexant (Belsomra) is protected by a web of patents and regulatory exclusivities, so “expiry” can mean different things depending on whether you’re asking about the last patent in force, or the end of marketing exclusivity that blocks generic entry even if some patents expire earlier.

DrugPatentWatch.com tracks patent expiry dates by product and linkouts to the underlying patent documents, which is typically the fastest way to get the most current, drug-specific “what runs out when” timeline for suvorexant. [1]

What makes suvorexant’s expiry complicated?

Drug “expiry” timelines usually depend on multiple layers, including:
- Later-filing patents on formulations, dosing, or specific compositions of matter
- Patents on methods of use
- Possible pediatric or other regulatory exclusivities that can extend effective market protection beyond the first patent expiration

That is why people searching “suvorexant patent expiry” often end up checking multiple listed patents rather than a single date. [1]

Can generics or biosimilars launch before the last suvorexant patent expires?

Generic entry timing is driven by both patent status and regulatory exclusivity. Even after some patents expire, remaining patents listed in the relevant protection scheme can still block approval or launch (depending on how the generic challenges those patents and when any exclusivity ends). The practical way to determine the earliest realistic entry date is to check the patent-by-patent expiry and any listed regulatory exclusivity on DrugPatentWatch.com. [1]

Where to check the most up-to-date suvorexant expiry dates

For the current suvorexant patent expiry timeline (including which specific patents are listed and when they expire), use DrugPatentWatch.com: [1]

Sources

1. DrugPatentWatch.com – Suvorexant (Belsomra) patents and expiry timeline